We harness innovative technologies to create genetically superior animals for progressive farmers, and link our pricing to the performance of our products on-farm.

CREATE DIFFERENTIATED AND SUSTAINABLE PROPRIETARY GENETIC SOLUTIONS

Strategic Priorities

We harness the latest technologies and talent to continuously improve the genetics of our own herds and resulting product offering. We protect our unique position by carefully selecting who we sell our genetics and technology to, and on what terms.

What does success look like?

Genetic Gain

Creating better breeding animals for farmers, measured against indices comprising economic traits that help to drive farmers’ productivity and sustainability.

Net Merit Rankings
Monitors how many of our bulls are highly ranked, based on economically relevant traits for farmers.
DEFINITION: The number of our generally available Holstein bulls listed in the top 100 Genomic Net Merit US$ rankings for genomically tested sires and the top 100 Net Merit rankings for daughter proven sires.
PERFORMANCE: Genus continues to maintain a leadership position with its strength in genomic bulls, which over time will become daughter proven bulls. This is mainly driven by the large proportion of high-quality bulls sourced from our proprietary breeding programme, De Novo1.
1De Novo Genetics LLC is 51% owned by Genus.
Porcine Genetic Improvement Index
Measures the genetic improvement we achieve in our porcine nucleus herds, which ultimately filters down to our customers’ farms.
DEFINITION: The index measures the marginal improvement in customers’ US$ profitability, per commercial pig per year, on a rolling three-year average. Prior years’ index ratings have been updated, to reflect the latest results from genomic selection and the economic values of pork production.
PERFORMANCE: Genus continues to deliver high rates of genetic improvement through improving technical processes for genomic evaluation, crossbred performance testing and expanding the elite nucleus populations.

SERVE PROGRESSIVE PROTEIN PRODUCERS EFFECTIVELY

Strategic priorities

We focus our offering on progressive livestock farmers, who are data driven and results focused. We tailor our products and services to  maximise their performance on their farms. We serve different markets in different ways to manage cost and risk effectively.

What does success look like?

Volume Growth

Growing volumes, particularly with progressive livestock farmers.

 

Porcine Volume Growth
Tracks the growth in the number of commercial pigs with PIC genetics globally.
DEFINITION: The change in volume of both direct and royalty animal sales, using a standardised MPEs measure of commercial slaughter animals that contain our genetics.
PERFORMANCE: Porcine volumes grew by 13% to 171 million MPEs. China’s volumes were particularly strong due to a sharp increase in customer breeding projects following the ASF outbreak in the prior year. Excluding China, volumes were up 6% with strong growth in Brazil, Germany and Spain. Volumes under royalty contracts grew by 8% with all regions contributing.
Dairy and Beef Volume Growth
Tracks our global unit sales growth in dairy and beef.
DEFINITION: The change in dairy, beef and sorted units of semen and embryos delivered or produced for customers in the year.
PERFORMANCE: Bovine volumes improved 8% to 21.2 million units, with strong growth in Latin America and Asia and all regions contributing. Sexed volumes were up 47%, reflecting strong growth in Sexcel, which also influenced the use of beef-on-dairy genetics, supporting a 17% increase in global beef volumes.

SHARE IN THE VALUE DELIVERED

strategic priorities

We aim to capture an appropriate share of the value we deliver to customers, aligning our interests with theirs. We demonstrate the value of our genetics on farm through validation trials and data, and link our pricing to genetic indices and our customers’ productivity.

What does success look like?

Profitability 

Generating profit resulting from the performance of our products in customers’ systems.

 

Adjusted Operating Profit Per Market Pig Equivalent
Monitors porcine profitability by unit.
DEFINITION: Net porcine adjusted operating profit globally, expressed per MPE. Results include our share of Agroceres PIC, our Brazilian joint venture.
PERFORMANCE: Adjusted operating profit per MPE was £0.61, up £0.01 (up £0.02 in constant currency). This was primarily due to strong breeding stock sales in China and global royalty contract growth partially offset by investments to expand the global nucleus elite farm network.
Bovine Adjusted Operating Profit Per Dose
Monitors bovine profitability by dose.
DEFINITION: Bovine adjusted operating profit globally, expressed per dose of semen or embryo delivered or produced for customers.
PERFORMANCE: Adjusted operating profit per dose was £0.55, up £0.05 (up £0.12 in constant currency). This was due to the strong sales growth of our premium Sexcel product, while also lowering its production costs to manufacture, and leveraging the world class sales and product development platforms.

* De Novo Genetics LLC is 51% owned by Genus.

arrow